U.S., Nov. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07241169) titled 'The Safety and Efficacy of ZVS106e in the Treatment of IRDs Caused by Biallelic Mutations in ABCA4' on Sept. 29.
Brief Summary: To evaluate the preliminary safety of monocular and single subretinal injection of ZVS106e injection in the treatment of patients with hereditary retinal degeneration (ABCA4-IRDS) caused by ABCA4 biallelic mutations.
Study Start Date: Dec. 26
Study Type: INTERVENTIONAL
Condition:
Stargardt
Intervention:
DRUG: ZVS106e
ZVS106e is A colorless, clear and transparent liquid, containing two active ingredients, ZVS106E-A and ZVS106E-B. The viral vectors used for both active ingredients are rAAV8
Recruitmen...